Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Natural treatment has an antibiotic-like effect on HPV

By PR Newswire | May 8, 2017

Natural treatment has an antibiotic-like effect on viruses; CBCD reports publication of a new clinical study of Gene-Eden-VIR/Novirin.

Most drugs target symptoms. Antibiotics are different. Antibiotics target the cause of the disease, and as a result, cure the disease. Almost all other drugs, such as those that lower cholesterol or blood pressure, target symptoms. These drugs don’t cure the disease. They reduce symptoms, for a while. But because of their short term effect, patients need to take them again and again, for life.

Unlike these drugs, patients take antibiotics for a limited time and clear the infection. The effect of antibiotics is so remarkable, that Dr. Friedman and Dr. Friedland list antibiotics as one of “Medicine’s 10 Greatest Discoveries.”

Now, the Center for the Biology of Chronic Disease (CBCD) announces the publication of a clinical study that shows that Gene-Eden-VIR/Novirin has an antibiotic-like effect on viruses.

Antibiotics completely clear the bacteria in infected individuals. The published clinical study shows that Gene-Eden-VIR/Novirin, like antibiotics, completely clears the human papillomavirus (HPV) in infected individuals. After 12 months of treatment, 100 percent of the participants in the study were HPV free vs. only 53, 52, 65, 20, and 77 percent in the five untreated groups. Within a year, Gene-Eden-VIR/Novirin completely wiped out the virus.

In contrast, 23-80 percent of the untreated participants were still infected. Currently, there are no treatments that get rid of latent viruses, and specifically, the latent HPV. Gene-Eden-VIR/Novirin is the first of its kind.

The study was published in the leading peer-reviewed medical journal Drug Design, Development and Therapy.1 The study is also explained in a video with Dr. Hanan Polansky and Dr. Edan Itzkovitz.

According to Polansky, the lead author of the study, “When I first saw the results, I was shocked. Doctors tell you that it is impossible to get rid of a latent virus. Once you are infected, you are infected for life. Well, our results say: ‘Hold on a second! This universal belief is wrong.’ Our study shows that there is a way to get rid of a latent virus.”

Gene-Eden-VIR/Novirin consists of five natural ingredients, quercetin, green tea extract, cinnamon extract, licorice extract, and selenium. The Gene-Eden-VIR/Novirin formula is patent protected. The formula was developed to target latent (hidden) viruses. Two previous clinical studies showed that Gene-Eden-VIR/Novirin is effective against genital herpes,2,3 and that it has antiviral properties.4

In summary, the new paper reports the results of a clinical study that tested the effect of oral treatment with Gene-Eden-VIR/Novirin on the human papillomavirus (HPV). The study showed that Gene-Eden-VIR/Novirin has an antibiotic-like effect on viruses.

References

  1. Polansky H, Itzkovitz E, Javaherian A. Human papillomavirus (HPV): systemic treatment with Gene-Eden-VIR/Novirin safely and effectively clears virus. Drug Des Devel Ther. 2017 March 3, 11: 575—583;10:2713-22
  2. Polansky H, Itzkovitz E, Javaherian A. Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases. Clin Transl Med. 2016 Dec;5(1):40.
  3. Polansky, H. Javaherian, A. Itzkovitz E. Clinical study in genital herpes: natural Gene-Eden-VIR/Novirin versus acyclovir, valacyclovir, and Famciclovir. Drug Design, Development and Therapy 2016:10 2713-2722
  4. Polansky H, Itzkovitz E. Gene-Eden-VIR is antiviral: results of a post marketing clinical study. Pharmacol Pharm. 2013;4(6A):1-8

(Source: PR Newswire)

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery, Hepatology
Tagged With: HPV, Novirin
 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE